Trial Profile

A clinical trial for immediate release tablet formulation for IDE196

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darovasertib (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors IDEAYA Biosciences

Most Recent Events

08 Nov 2019 New trial record
31 Oct 2019 According to an IDEAYA Biosciences media release, the company announced that an immediate release tablet formulation for IDE196 is on-track for introduction in the clinic in Q1 2020, as a potential registration and commercial formulation.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com